In vivo screening
The company uses a direct in vivo screening system that provides quantitative readouts from mouse brains in two days.
Source: LinkedIn company description · Retrieved October 13, 2026
NucleoTech is advancing an internal pipeline that begins with a brain-deliverable CD20 therapeutic for progressive multiple sclerosis and is preparing carrier candidates for antibody and RNA delivery collaborations.
The company combines AI-based protein design with experimental workflows to screen RMT binders across multiple receptor pathways and evaluate sequence variants in vivo. Its platform supports antibodies, ASOs, and other biologics.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company uses a direct in vivo screening system that provides quantitative readouts from mouse brains in two days.
Source: LinkedIn company description · Retrieved October 13, 2026
The company combines AI-based protein design and experimental workflows to screen RMT binders across multiple receptor pathways.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 18, 2026 and October 7, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.